Mono-Therapy: ELORES (Ceftriaxone/Sulbactam 1.5 g/Vial Powder for Solution for Injection/Infusion) is indicated for the treatment of the following infections when caused by susceptible organisms, which could include ESBL/MBL producing multidrug resistant pathogens: Lower Respiratory tract infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens, Pseudomonas aeruginosa, A. baumanii.
Urinary Tract Infections caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae, E. faecalis, A. baumanii, P. aeruginosa.
Acute bacterial septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Staphylococcus albus, Haemophilus influenzae or Klebsiella pneumoniae, A. baumanii, P. aeruginosa.
Infections of bones and joints caused by Staphylococcus aureus, Escherichia coli, Proteus mirabilis, Proteus vulgaris, Citrobacter spp, Klebsiella pneumoniae or Enterobacter species, P. aeruginosa, A. baumanii.
Infections of skin and Soft-tissue Infections caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii, *Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species, P. aeruginosa.
Chronic suppurative otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis, Klebsiella pneumoniae, A. baumanii, P. aeruginosa, Staphylococcus aureus.
Surgical prophylaxis: Reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated.
Combination Therapy: Because of broad spectrum of activity of Ceftriaxone sodium, Sulbactam sodium, and Disodium edetate, most infections can be treated adequately with ELORES alone. However, in some cases ELORES may be combined with other antibiotics like vancomycin, amsacrine, aminoglycosides, and fluconazole. When any of these drugs are to be administered concomitantly with ceftriaxone by intermittent intravenous infusion, it is recommended that they be given sequentially, with thorough flushing of the intravenous lines (with one of the compatible fluids) between the administrations, as they are physically incompatible with ELORES in admixtures. If an aminoglycoside is used renal function should be monitored during the course of therapy (see use in Renal Dysfunction under Precautions).
Culture sensitivity studies should be performed to identify the causative organism and their susceptibility tests to ELORES.
ELORES is useful as presumptive therapy in the indicated conditions prior to the identification of causative organisms because of its broad spectrum bactericidal activity against gram-positive and gram-negative aerobic and anaerobic organisms. Clinical trials demonstrated that ELORES is effective against ESB/MBL producing Gram-negative and gram positive pathogens. The decision to continue therapy with the drug should be based on results of susceptibility tests, the severity of infection, the response of the patient, and the important additional considerations contained in the Warnings section.